<DOC>
	<DOCNO>NCT00110851</DOCNO>
	<brief_summary>This study design evaluate safety efficacy PN2034 administer type 2 diabetic concomitant rosiglitazone metformin ( Avandamet ) therapy measure change glycosylated hemoglobin ( HbA1c ) level baseline Week 12 . Also study evaluate effect PN2034 glucose control measure fast plasma glucose ( FPG ) fast lipid level : triglyceride , total cholesterol , high-density lipoprotein ( HDL ) , low-density lipoprotein ( LDL ) , low-density lipoprotein ( VLDL ) .</brief_summary>
	<brief_title>Safety Efficacy Study PN2034 Type 2 Diabetes Patients Concomitant Rosiglitazone Metformin ( Avandamet )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>diagnose type 2 diabetes mellitus 21 72 year age take rosiglitazone metformin ( Avandamet ) least 3 month , stable dose rosiglitazone ( Avandamet ) least 2 month glycosylated hemoglobin ( HbA1c ) level &gt; /=7.5 % &lt; /=10.0 % fast blood sugar level &gt; /= 125 mg/dL &lt; /= 279 mg/dL BMI 2643 kg/m2 direct bilirubin &lt; 1.5x upper limit normal ( ULN ) serum creatinine &lt; 1.5 mg/dL ( male ) &lt; 1.4 mg/dL ( female ) blood urea nitrogen ( BUN ) &lt; /=40 mg/dL clinical laboratory parameter ( hematology , serum chemistry , urinalysis ) within normal limit clinically significant ECG normal , abnormality clinically significant surgically sterile , postmenopausal , use adequate contraception negative pregnancy test Screening willing able sign inform consent form diagnose type 1 diabetes mellitus history ketoacidosis treatment insulin , TZDs ( exclude rosiglitazone ) oral inject antidiabetic ( exclude metformin Avandamet ) within 3 month prior screen study treatment change lipidlowering medication within 2 month screen take systemic corticosteroid within 1 month prior screen study treatment history current/active cardiovascular disease significant current pulmonary condition significant thyroid disease CPK value &gt; 3x ULN female pregnant lactate systolic BP &gt; 160 mm Hg diastolic BP &gt; 90 mm Hg screen previous current history cancer , basal cell stage 1 squamous cell carcinoma skin , remission within 5 year prior randomization liver function test ( ALT , AST , ALP ) &gt; 2 time ULN , active liver disease screen history positive HIV positive hepatitis B test screen weight loss gain &gt; /= 15 lb within 3 month screen history substance abuse ( include alcohol abuse ) within 2 year prior screen donate and/or receive blood blood product within 3 month prior randomization take investigational study medication within 30 day prior screen study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>diabetes , type 2</keyword>
</DOC>